{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:11:55Z","timestamp":1795057915162,"version":"4.10.2"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jchf.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T16:51:26Z","timestamp":1551113486000},"page":"228-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":193,"title":["Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"7","author":[{"given":"Miranda","family":"Merrill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy K.","family":"Sweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2019.01.003_bib1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/ejhf.327","article-title":"Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response","volume":"17","author":"Kao","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.003_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/01.HYP.0000124251.06056.8e","article-title":"Relations of serum aldosterone to cardiac structure gender-related differences in the Framingham heart study","volume":"43","author":"Vasan","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.jchf.2019.01.003_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2019.01.003_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1752-8062.2009.00094.x","article-title":"Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction","volume":"2","author":"Kanashiro-Takeuchi","year":"2009","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jchf.2019.01.003_bib5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.01.003_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2019.01.003_bib7","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT\u2014new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.01.003_bib8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/bmj.2.5402.177","article-title":"Human Experimentation: Code of ethics of the world medical association","volume":"2","author":"Rickham","year":"1964","journal-title":"Br Med J"},{"key":"10.1016\/j.jchf.2019.01.003_bib9","first-page":"180","article-title":"Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations","volume":"1","author":"Bristow","year":"2016","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jchf.2019.01.003_bib10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/CIRCULATIONAHA.117.028002","article-title":"Physical activity and prognosis in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist)","volume":"136","author":"Hegde","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2019.01.003_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.003_bib12","first-page":"653","article-title":"Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial","volume":"6","author":"Vaduganathan","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2019.01.003_bib13","first-page":"689","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial","volume":"6","author":"Cikes","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2019.01.003_bib14","first-page":"570","article-title":"The frailty syndrome and outcomes in the TOPCAT trial","author":"Sanders","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.003_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/CIRCHEARTFAILURE.112.970061","article-title":"Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial","volume":"5","author":"Lam","year":"2012","journal-title":"Circ Hear Fail"},{"key":"10.1016\/j.jchf.2019.01.003_bib16","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1161\/CIRCULATIONAHA.106.673442","article-title":"Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure\u2014results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"115","author":"O\u2019Meara","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2019.01.003_bib17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.amjcard.2005.11.042","article-title":"Comparison of morbidity in women versus men with heart failure and preserved ejection fraction","volume":"97","author":"Deswal","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2019.01.003_bib18","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ahj.2007.03.016","article-title":"Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction","volume":"153","author":"Alla","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2019.01.003_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/eurjhf\/hfs026","article-title":"Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis","volume":"14","author":"Mart\u00ednez-Sell\u00e9s","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2019.01.003_bib20","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2019.01.003_bib21","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.01.003_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.01.003_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.01.003_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction bertram","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2019.01.003_bib25","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0008-6363(01)00479-5","article-title":"Renin angiotensin system and gender differences in the cardiovascular system","volume":"53","author":"Fischer","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jchf.2019.01.003_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.pcad.2006.08.011","article-title":"Role of gender in heart failure with normal left ventricular ejection fraction","volume":"49","author":"Regitz-Zagrosek","year":"2007","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jchf.2019.01.003_bib27","first-page":"180","article-title":"Detection and management of geographic disparities in the TOPCAT trial: lessons learned and derivative recommendations public access","volume":"1","author":"Bristow","year":"2016","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jchf.2019.01.003_bib28","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2012.08.004","article-title":"Endothelial dysfunction: a pathophysiologic factor in heart failure with preserved ejection fraction","volume":"60","author":"Lam","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919300095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177919300095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:50:16Z","timestamp":1761972616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177919300095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2213177919300095"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2019.01.003","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}